/

Empresas

In

No verificado

Incyte

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

107 Comunicados de prensa

Ver todos los comunicados de prensa

13/06/2026

Eventos

Biotecnología

Farmacéutica

Salud

Medicina - Varios

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Fuente

Editor

1.00

0

13/06/2026

Eventos

Oncología

Higiene alimentaria

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Fuente

Editor

1.00

0

08/06/2026

Web y redes sociales

Mercado de valores

Telefonía

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Fuente

Editor

1.00

0

30/05/2026

Oncología

Salud

Medicina - Varios

Farmacéutica

Cardiología

Biotecnología

Eventos

Industria

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

Fuente

Editor

1.00

0

26/05/2026

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Web y redes sociales

Eventos

Industria

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Fuente

Editor

1.00

0

12/05/2026

Eventos

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Fuente

Editor

1.00

0

01/05/2026

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Fuente

Editor

1.00

0

29/04/2026

Eventos

Web y redes sociales

Oncología

Salud

Ciencia

Farmacéutica

Biotecnología

Incyte to Present at Upcoming Investor Conferences

Fuente

Editor

1.00

0

28/04/2026

Mercado laboral

Oncología

Salud

Ciencia

Farmacéutica

Biotecnología

Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

Fuente

Editor

1.00

0

28/04/2026

Web y redes sociales

Telefonía

Mercado de valores

Biotecnología

Farmacéutica

Salud

Oncología

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0